Dual Antiplatelet Therapy Beyond 90 days in Symptomatic Intracranial Stenosis in the SAMMPRIS Trial
| Autor: | Eyad Almallouhi, Christine A Holmstedt, Line Abdul Rahman, Marc I. Chimowitz, George Cotsonis, Tanya N. Turan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Stroke rate Percutaneous Time Factors Post hoc Intracranial stenosis Hemorrhage Drug Administration Schedule Article 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Clinical endpoint Humans cardiovascular diseases Stroke Aged Aspirin business.industry Dual Anti-Platelet Therapy Rehabilitation Angioplasty Middle Aged medicine.disease Clopidogrel Intracranial Arteriosclerosis Treatment Outcome Cardiology Surgery Female Stents Neurology (clinical) Cardiology and Cardiovascular Medicine business 030217 neurology & neurosurgery Platelet Aggregation Inhibitors medicine.drug circulatory and respiratory physiology |
| Zdroj: | J Stroke Cerebrovasc Dis |
| ISSN: | 1532-8511 |
| Popis: | Background The safety and efficacy of dual antiplatelet use for symptomatic intracranial atherosclerosis beyond 90 days is unknown. Data from SAMMPRIS was used to determine if dual antiplatelet therapy (DAPT) beyond 90 days impacted the risk of ischemic stroke and hemorrhage. Methods This post hoc exploratory analysis from SAMMPRIS included patients who did not have a primary endpoint within 90 days after enrollment (n = 397). Patients in both the aggressive medical management (AMM) and percutaneous transluminal angioplasty and stenting (PTAS) arms were included. Baseline features and outcomes during follow-up were compared between patients who remained on DAPT beyond 90 days (on clopidogrel) and patients who discontinued clopidogrel and remained on aspirin alone at 90 days (off clopidogrel) using Fisher's exact tests. Results The stroke rate was numerically lower in the group on clopidogrel vs off clopidogrel among both the AMM alone arm (6.0% versus 10.8%, p = 0.31) and the PTAS arm (8.7% versus 9.8%; p = 0.82), but the difference was not significant. The major hemorrhage rates were numerically higher in the group on clopidogrel vs. off clopidogrel group among both the AMM alone arm (4.0% versus 2.5%; p = 0.67) and the PTAS arm (10.9% versus 3.5%; p = 0.08), but were not significant. Conclusion This exploratory analysis suggests that prolonged DAPT use may lower the risk of stroke in medically treated patients with intracranial stenosis but may increase the risk of major hemorrhage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect